Summary:
Bakersfield Dermatology and Skin Cancer Medical Group is conducting a phase III, multicenter, double-blind, randomized, parallel-arm, placebo-controlled study to evaluate the safety and efficacy of Adalimumab for treatment of nail Psoriasis in subjects with chronic plaque psoriasis.
Qualified Participants Must:
• Be at least 18 years of age
•
Have s clinical diagnosis of chronic plaque psoriasis (6 months stable disease)
•
Discontinue any current use of certain psoriasis medications
•
Have at least one fingernail with nail psoriasis
•
Self-administer the study drug
•
Be willing to have blood tests taken at each study visit
Qualified Participants May Receive:
Compensation for travel to visits after screening visit.